| Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016 |
83 |
| Renal tubule injury: a driving force toward chronic kidney disease |
68 |
| Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices |
61 |
| Acute kidney injury from sepsis: current concepts, epidemiology, pathophysiology, prevention and treatment |
49 |
| Renoprotective effects of sodium-glucose cotransporter-2 inhibitors |
45 |
| Long-term risk of adverse outcomes after acute kidney injury: a systematic review and meta-analysis of cohort studies using consensus definitions of exposure |
44 |
| Advanced glycation end products in the pathogenesis of chronic kidney disease |
42 |
| Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference |
34 |
| Factors leading to the discard of deceased donor kidneys in the United States |
34 |
| Alport syndrome: a unified classification of genetic disorders of collagen IV alpha 345: a position paper of the Alport Syndrome Classification Working Group |
34 |
| Increasing access to integrated ESKD care as part of universal health coverage |
32 |
| The macrophage phenotype and inflammasome component NLRP3 contributes to nephrocalcinosis-related chronic kidney disease independent from IL-1-mediated tissue injury |
32 |
| Analysis from the EMPA-REG OUTCOME (R) trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics |
32 |
| Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin |
30 |
| Analyses of the short- and long-term graft survival after kidney transplantation in Europe between 1986 and 2015 |
29 |
| Non-HLA agonistic anti-angiotensin II type 1 receptor antibodies induce a distinctive phenotype of antibody-mediated rejection in kidney transplant recipients |
28 |
| Kidney disease in the setting of HIV infection: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference |
28 |
| HIF-1 alpha inducing exosomal microRNA-23a expression mediates the cross-talk between tubular epithelial cells and macrophages in tubulointerstitial inflammation |
28 |
| Dialysis initiation, modality choice, access, and prescription: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference |
28 |
| A sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor-dependent pathway after renal injury in mice |
28 |
| Regulated necrosis in kidney ischemia-reperfusion injury |
28 |
| IgA nephropathy and IgA vasculitis with nephritis have a shared feature involving galactose-deficient IgA1-oriented pathogenesis |
26 |
| Sodium-glucose cotransporter 2 inhibition normalizes glucose metabolism and suppresses oxidative stress in the kidneys of diabetic mice |
26 |
| Cellular and molecular pathways of renal repair after acute kidney injury |
26 |
| Comparison of organ donation and transplantation rates between opt-out and opt-in systems |
25 |
| Monogenic causes of chronic kidney disease in adults |
24 |
| Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference |
24 |
| Predicting timing of clinical outcomes in patients with chronic kidney disease and severely decreased glomerular filtration rate |
24 |
| IL-17A improves the efficacy of mesenchymal stem cells in ischemic-reperfusion renal injury by increasing Treg percentages by the COX-2/PGE2 pathway |
23 |
| Noncoding RNAs in acute kidney injury |
23 |
| Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference |
22 |
| C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy |
22 |
| Whole exome sequencing frequently detects a monogenic cause in early onset nephrolithiasis and nephrocalcinosis |
22 |
| Markers of early progressive renal decline in type 2 diabetes suggest different implications for etiological studies and prognostic tests development |
22 |
| Neutrophil peptidyl arginine deiminase-4 has a pivotal role in ischemia/reperfusion-induced acute kidney injury |
21 |
| A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis |
21 |
| Increased podocyte Sirtuin-1 function attenuates diabetic kidney injury |
21 |
| Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease |
21 |
| Fibroblast growth factor 1 ameliorates diabetic nephropathy by an anti-inflammatory mechanism |
21 |
| M2 macrophages in kidney disease: biology, therapies, and perspectives |
21 |
| Novel ACE2-Fc chimeric fusion provides long-lasting hypertension control and organ protection in mouse models of systemic renin angiotensin system activation |
20 |
| Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis |
20 |
| Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome |
19 |
| Biglycan evokes autophagy in macrophages via a novel CD44/Toll-like receptor 4 signaling axis in ischemia/reperfusion injury |
19 |
| Reduced cortical oxygenation predicts a progressive decline of renal function in patients with chronic kidney disease |
19 |
| Kidney-on-a-chip: untapped opportunities |
19 |
| Knockout of the urate oxidase gene provides a stable mouse model of hyperuricemia associated with metabolic disorders |
19 |
| Arterial inflammaging drives vascular calcification in children on dialysis |
19 |
| Primary outcomes of the Monitoring in Dialysis Study indicate that clinically significant arrhythmias are common in hemodialysis patients and related to dialytic cycle |
18 |
| C3 glomerulopathy associated with monoclonal Ig is a distinct subtype |
18 |
